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Palmoplantar keratoderma is a heterogeneous group of hereditary and acquired disorders characterized by abnormal thickening
of palms and soles. Hypothyroidism is an unusual cause of palmoplantar keratoderma, rarely reported in the literature. We report
a case of a 43-year-old woman presented with a 3-month history of a diﬀuse palmoplantar hyperkeratosis unresponsive to topical
keratolytics and corticosteroids. Her past medical and family histories were unremarkable. She complained of recent asthenia,
mood changes and constipation. Laboratory evaluation revealed an autoimmune thyroiditis with hypothyroidism. Other causes
of acquired palmoplantar keratoderma were excluded. After hormonal replacement therapy institution, a gradual improvement
of skin condition was observed. The diagnosis of underlying causes for acquired palmoplantar keratoderma can be a diﬃcult
task; however its recognition is essential for successful treatment results. Although a very rare association, hypothyroidism must be
suspectedinpatientswithacquiredpalmoplantarkeratoderma,particularlywhenitoccursinassociationwithsystemicsymptoms.
1.Introduction
Palmoplantar keratoderma is a heterogeneous group of here-
ditary and acquired disorders characterized by abnormal
thickening of palms and soles. Acquired palmoplantar kera-
toderma has been associated to numerous underlying causes,
such as psoriasis, lichen planus, pityriasis rubra pilaris,
eczema, Reiter’s syndrome, fungal infections, keratoderma
climactericum, trauma, drugs, chemicals and malignancies
[1–4].
Thyroid disorders have a high prevalence in medical
practice. Hypothyroidism is a common endocrine disorder
resulting from deﬁciency of thyroid hormones, most fre-
quently caused by autoimmune thyroiditis. Many of the
most common symptoms and signs of hypothyroidism
are nonspeciﬁc [5]. The hypothyroid state is associated
with a wide variety of cutaneous ﬁndings [6]; however,
its association with palmoplantar keratoderma is seldom
described in the medical literature.
2. Case Presentation
A 43-year-old black woman presented with a 3-month
history of symmetric, diﬀuse and yellowish hyperkeratosis of
palmsandsoles.Plantarsurfaceswerethemostaﬀected,with
painful ﬁssures (Figures 1 and 2). A progressive worsening
was seen in the last 2 months, despite treatment with topical
antifungals, oral terbinaﬁne and topical corticosteroids. Dry
skin with generalized pruritus was also observed. Neck
examination was unremarkable. The remainder physical
examination (including nails, mucosae and hair) was nor-
mal. Asthenia, mood changes with emotional lability, con-
stipation and menstrual irregularities were present for the
last 4 months. Her past medical history was unremarkable.
She denied the use of any medication. Family history was
negative for dermatological diseases.
A complete laboratory and imaging evaluation was per-
formed in order to investigate possible infectious, systemic,
or malignant conditions. Routine laboratory tests were nor-
mal, except for elevated total cholesterol (295mg/dL) and
LDL cholesterol (205mg/dL). Thyroid function tests reve-
aled an elevated thyroid stimulating hormone (17,5U/mL;
normal range 0,35–4,94) and diminished free triiodothy-
ronine (1,45pg/mL; normal range 1,71–3,71) and free
thyroxine (0,46ng/dL; normal range 0,7–1,48). Circulating
antibodies to thyroid peroxidase were elevated (534U/mL)
and thyroglobulin antibody was negative. Other immuno-
logical tests (rheumatoid factor, antinuclear antibodies,2 Case Reports in Medicine
Figure 1: Diﬀuse plantar keratoderma, with painful ﬁssures.
Figure 2: Diﬀuse palmar keratoderma with a yellowish hue.
antidoublestrandedDNAantibodies,antiextractablenuclear
antigen antibodies and complement) were also normal or
negative. Infections by hepatitis B and C viruses, human
immunodeﬁciency virus 1 and 2, Treponema pallidum and
intestinal parasites were excluded. Fungal cultures from skin
and nails were negative. Tumor markers (CEA, CA 19-9,
CA-125, CA 15-3, β2-microglobulin and AFP) were nor-
mal. Abdominal and pelvic ultrasound, mammography and
chest radiograph were unremarkable. A thyroid ultrasound
showed a homogeneous ultrasonographic thyroid image and
excluded nodules and goitre. The patient refused to give
consent for a skin biopsy.
Initially, empirical treatment with emollients, topical
keratolytics (urea, salicylic acid) and isotretinoin 20mg/day
was started. Despite those treatments, worsening of palmo-
plantar keratoderma was observed. Skin xerosis improved
after treatment with topical emollients. Later, with the diag-
nosis of primary hypothyroidism secondary to autoimmune
thyroiditis, the patient was referred to Internal Medicine
Department and therapy with levothyroxine (0, 1mg/day)
was started. A slow and progressive improvement was seen,
with partial and complete clinical remission of cutaneous
ﬁndingsat3and9monthsofhormonalreplacementtherapy,
respectively (Figures 3 and 4). Systemic symptoms had also
an excellent and sustained response to the treatment. After
Figure 3: Improvement of plantar keratoderma after 9 months of
levothyroxine therapy.
Figure 4: Complete clinical remission of palmar hyperkeratosis at
9 months of levothyroxine therapy.
24 months of follow-up, she continues levothyroxine with
normal thyroid function tests and no recurrences of the
dermatosis.
3. Discussion
Palmoplantar keratodermas are a diverse group of disorders
characterized by thickening of the skin of the palms and soles
caused by excessive keratin. The palmoplantar keratodermas
can be divided based on whether they are inherited or
acquired. Hereditary palmoplantar keratodermas tend to
occur in infancy, with positive family history (autosomal
dominant or recessive) and can be accompanied by associ-
atedfeatures(lesionsofnonvolarskin,hair,teeth,nails,sweat
glandsand/orabnormalitiesofotherorgans)[7,8].Acquired
palmoplantar keratoderma can be deﬁned as a nonheredi-
tary, non-frictional hyperkeratosis of the palms and/or soles
that involves more than half of the surface of involved acral
areas [1]. Just as the hereditary forms, it can be classiﬁedCase Reports in Medicine 3
into 3 clinical patterns of epidermal involvement: diﬀuse,
focal and punctuate. Acquired palmoplantar keratoderma
is a multietiological disorder; therefore, a comprehensive
history and complete physical examination are essential in
the diagnostic approach of these patients.
The functioning of the skin depends on the general
status of the body and it is controlled by hormones, like the
thyroid. Hypothyroidism can be associated with dry skin,
hypohidrosis, generalized myxedema, purpura, ecchymosis,
xantomas, carotenodermia, pruritus and pyodermitis [6, 9].
Autoimmune thyroiditis, also called Hashimoto thyroiditis,
is a thyroid disease that occurs as a result of an immune
response directed against the thyroid gland. It is the most
frequent cause of hypothyroidism. Laboratorial ﬁndings
include increased thyroid stimulating hormone (TSH), low
thyroxine, hypercholesterolemia and the presence of thyroid
auto-antibodies [10].
Hypothyroidism has been rarely associated with palmo-
plantar keratoderma. To our knowledge, only 8 cases have
been reported in the literature [11–17]. This uncommon
association was ﬁrst described in 1952 by Shaw et al. [11]. In
1977,TanandSarkani[12]describedmyxedemawithpalmar
keratoderma.Later,in1986,Hodaketal.[13]r eport edacase
of a 63-year-old female with a 13-year history of intractable
severe hyperkeratosis of the hands and feet associated with
myxedema. A striking improvement was seen 3 months after
institution of substitution therapy with thyroid hormone.
Since then, 5 similar cases have been reported [14–17]. In
the majority of the patients, hypothyroidism was caused
by autoimmune thyroiditis [14, 15, 17]. Distinctive clinical
features of keratoderma include a yellowish hue, marked
severity, diﬀuse involvement of the soles and more limited
palmar involvement, lack of response to topical corticos-
teroids and keratolytics and a rapid response to thyroid
hormone replacement. Histopathological ﬁndings have been
unspeciﬁc, with marked hyperkeratosis and acanthosis. In
contrast to all previous published cases, in which myxedema
was present, in our case the clinical examination was normal,
except for the presence of palmoplantar keratoderma and
dry skin. The systemic complaints of our patient, such
as asthenia, constipation and menstrual irregularities were
unspeciﬁc and could be easily attributed to the aging process
and/or to psychological stress. In all previous reports, a lack
of response to topical corticosteroids and keratolytics was
also observed. This fact contrasts with the excellent clinical
response to thyroid hormonal replacement, with complete
clinical remission after 1 month [14] to 9 months of therapy
[15]. Similarly, in our case, a sustained clinical response to
levothyroxine treatment was observed, supporting a causal
relationship between hypothyroidism and palmoplantar ker-
atoderma. Its etiopathogenesis remains not well understood,
but it may be associated with a disturbance of intercellular
stratum corneum lipids [15].
Acquired palmoplantar keratoderma due to hypothy-
roidism is a reversible condition and its recognition is
essential for successful treatment results. Although a rare
association, hypothyroidism should be considered in the dif-
ferential diagnosis of acquired palmoplantar keratoderma.
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